— The monoclonal antibodies developed are agaonistic monoclonal antibodies. These antibodies can help in enhancing the immune system by activating dendritic cell subsets. Furthermore, these antibodies are unique, as they can activate Dendritic cells without the need for cross-linking the receptor.
— Dr. Hiroko Yano and Dr. Albert Kim, and their research teams at the Washington University School of Medicine in St. Louis developed and extensively evaluated a novel therapeutic approach using DNMT inhibitors to treat Huntington’s Disease (HD) and other neurodegenerative disorders. Currently D…
— Technology Description
Prof. Jeffrey Gordon and his colleagues have developed an inexpensive food formulation that could treat malnutrition and a range of associated health problems by repairing the gut microbiome. Children who are malnourished are currently treated with supplemental nutrition tha…
— Technology Description
An interdisciplinary team of researchers at Washington University have developed a sensitive, shelf-stable, label-free system for quickly quantifying biomarkers in point-of-care settings (e.g., office, ambulance or battlefield). Localized surface plasmon resonance (LSPR) off…
— This is a monoclonal antibody specific for NT-Pro BNP and can be used singly in a competitive immunoassay to measure the amount of this analyte in blood samples for the purpose of diagnosis or monitoring of congestive heart failure. In addition, it could be used in a sandwich immunoassay with a mono…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
